1. Home
  2. EDSA vs AMBO Comparison

EDSA vs AMBO Comparison

Compare EDSA & AMBO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EDSA
  • AMBO
  • Stock Information
  • Founded
  • EDSA 2015
  • AMBO 2000
  • Country
  • EDSA Canada
  • AMBO United States
  • Employees
  • EDSA N/A
  • AMBO N/A
  • Industry
  • EDSA Biotechnology: Pharmaceutical Preparations
  • AMBO Other Consumer Services
  • Sector
  • EDSA Health Care
  • AMBO Real Estate
  • Exchange
  • EDSA Nasdaq
  • AMBO Nasdaq
  • Market Cap
  • EDSA 6.2M
  • AMBO 7.1M
  • IPO Year
  • EDSA N/A
  • AMBO 2010
  • Fundamental
  • Price
  • EDSA $2.45
  • AMBO $2.56
  • Analyst Decision
  • EDSA Strong Buy
  • AMBO
  • Analyst Count
  • EDSA 1
  • AMBO 0
  • Target Price
  • EDSA $21.00
  • AMBO N/A
  • AVG Volume (30 Days)
  • EDSA 32.2K
  • AMBO 20.9K
  • Earning Date
  • EDSA 05-09-2025
  • AMBO 12-30-2024
  • Dividend Yield
  • EDSA N/A
  • AMBO N/A
  • EPS Growth
  • EDSA N/A
  • AMBO N/A
  • EPS
  • EDSA N/A
  • AMBO 0.11
  • Revenue
  • EDSA N/A
  • AMBO $9,392,000.00
  • Revenue This Year
  • EDSA N/A
  • AMBO N/A
  • Revenue Next Year
  • EDSA N/A
  • AMBO N/A
  • P/E Ratio
  • EDSA N/A
  • AMBO $23.61
  • Revenue Growth
  • EDSA N/A
  • AMBO 2.50
  • 52 Week Low
  • EDSA $1.55
  • AMBO $1.00
  • 52 Week High
  • EDSA $5.59
  • AMBO $5.55
  • Technical
  • Relative Strength Index (RSI)
  • EDSA 53.34
  • AMBO 47.64
  • Support Level
  • EDSA $2.31
  • AMBO $2.42
  • Resistance Level
  • EDSA $2.55
  • AMBO $3.20
  • Average True Range (ATR)
  • EDSA 0.12
  • AMBO 0.42
  • MACD
  • EDSA -0.02
  • AMBO -0.05
  • Stochastic Oscillator
  • EDSA 48.28
  • AMBO 14.43

About EDSA Edesa Biotech Inc.

Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.

About AMBO Ambow Education Holding Ltd.

Ambow Education Holding Ltd is a provider of educational and career enhancement services in China. It operates through CP&CE Programs. The CP&CE Programs include tutoring services and career enhancement services. Geographically all the operations function in the United States and Foreign countries.

Share on Social Networks: